Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Valsartan It is another ARB with several
2025-02-25

Valsartan It is another ARB, with several reports for its beneficial effects on CV system both in preclinical and clinical studies. Valsartan treatment has reduced the levels of pentraxin 3, a marker for inflammation and is well tolerated in terms of side effects [17]. In BSCORE study, 90-day sec
-
br Acknowledgments This work was supported by grants
2025-02-25

Acknowledgments This work was supported by grants from the “Agence Nationale de la Recherche” ANR-09-CESA-006 program, the Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (Anses, Project n° 2012-2-077) and the Interdisciplinary Program “Longévité et Viei
-
Introduction Alzheimer s disease AD is a complex neurologica
2025-02-25

Introduction Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia resulting from synapse failure (Selkoe, 2002, Tanzi, 2005). The amyloid hypothesis maintains that the pivotal event in AD is the production of amyloid-β (Aβ) peptides following the prote
-
br Discussion Hepatic dysfunction in the metabolic syndrome
2025-02-25

Discussion Hepatic dysfunction in the metabolic syndrome is a driver of negative patient outcomes that requires more therapeutic options. The complexity of liver alterations in this disease – elevated de novo synthesis of fatty acids and cholesterol, reduced clearance of circulating atherogenic L
-
br Experimental section br Introduction NMDA
2025-02-25

Experimental section Introduction NMDA receptor-induced increases in AMPAR trafficking to the synaptic surface mediates changes in synaptic efficacy in a number of CGK733 regions (Shi et al., 1999, Sun et al., 2005, Frenkel et al., 2006). While this process has been linked to the regulated in
-
br cDNA cloning gene structure and chromosomal
2025-02-25

cDNA cloning, gene structure and chromosomal localization The cDNA for the leukocyte-type 12S-lipoxygenase was first cloned from porcine leukocytes [9], and later from mouse [10], [11], rat [12], [13], bovine [14] and rabbit [15] sources. The cDNA for the platelet-type 12S-lipoxygenase cDNA has b
-
br Discussion Elevated blood BCAA levels are
2025-02-25

Discussion Elevated blood BCAA levels are a common feature of a developed pathophysiological state characterized by obesity and IR [4]. It has been suggested that this profile is part of a panel of biomarkers able to predict the onset of more severe complications like diabetes in humans [14]. In
-
glucose transport proteins The lactam emerged as lead candid
2025-02-25

The lactam (6) emerged as lead candidate due to its high selectivity, outstanding potency (against ALK or in clinically known ALK mutants), low in vitro clearance, and low efflux potential. The lactam (6) was selected for further profiling against the resistant ALK mutants. Preclinical rat pharmacok
-
Interestingly intermittent high doses of AKT inhibitors have
2025-02-25

Interestingly, intermittent high doses of AKT inhibitors have been shown to be a more effective strategy both clinically and pre-clinically. High doses appear to be required for induction of apoptosis and intermittent schedules overcome the low therapeutic index of these compounds. This is particula
-
The obtained results indicate that even when the impairment
2025-02-25

The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate
-
Since the cloning of ARs in
2025-02-25

Since the cloning of ARs in the beginning of the 1990s, the efforts to characterize them have led to the accumulation of a substantial amount of experimental data. Decades of site-directed mutagenesis (SDM; Box 1) studies, in combination with pharmacological data and computational modeling, have pav
-
mecamylamine The UV vis and fluorescence
2025-02-25

The UV–vis and fluorescence spectra have been used to study the interaction between small chemical molecules and biomolecules (Punith and Seetharamappa, 2012). The UV mecamylamine peak of the protein changes with the microenvironment of the chromophore. That is, the peaks may show a certain degree
-
The geometry of two three four and
2025-02-25

The geometry of two, three, four and five Z-DQMD-FMK neutral radical ACh molecule complexes with various electronic configurations, i.e. with various multiplicities equal to 1, 2 and 4 (for ACh trimer) were determined using DFT with the unrestricted B97d/SVP potential/basis set in Gaussian09 progra
-
The AAP s policy statement on
2025-02-25

The AAP’s policy statement on childhood adversities is a call to the pediatric buy norethisterone to apply the knowledge toward developmental screening in clinical practice. It is a movement to increase education around childhood adversity as a public health crisis and to build trauma-informed care
-
br Conflict of interest br Acknowledgments br Introduction
2025-02-25

Conflict of interest Acknowledgments Introduction Inflammation is a protective response of the microcirculation to harmful stimuli. Yet, excessive inflammation is potentially harmful and a characteristic of many chronic diseases [1]. 5-Lipoxygenase (5-LO, EC1.13.11.34) contributes to the in
15838 records 20/1056 page Previous Next First page 上5页 1617181920 下5页 Last page